ARCUTIS BIOTHERAPEUTICS, INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 47.28 million shares for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-06.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2021-05-06
- ARCUTIS BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-03-31 was 47.28M shares, a 94.92% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-12-31 was 43.03M shares, a 1995.19% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-09-30 was 37.75M shares, a 1870.58% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-06-30 was 37.59M shares, a 2026.39% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 35.67M shares, a 1835.11% increase from fiscal 2019.
- ARCUTIS BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 1.84M shares, a 48.68% increase from fiscal 2018.
- ARCUTIS BIOTHERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 1.24M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-03-31 | 47.28M shares 10-Q · filed 2021-05-06 | 45.16M shares derived: average of 2 quarters · filed 2021-05-06 | 42.69M shares derived: average of 3 quarters · filed 2021-05-06 | 41.41M shares derived: average of 4 quarters · filed 2021-05-06 |
| 2020-12-31 | 43.03M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | 40.39M shares derived: average of 2 quarters · filed 2021-02-16 | 39.46M shares derived: average of 3 quarters · filed 2021-02-16 | 35.67M shares 10-K · filed 2021-02-16 |
| 2020-09-30 | 37.75M shares 10-Q · filed 2020-11-05 | 37.67M shares derived: average of 2 quarters · filed 2020-11-05 | 33.21M shares 10-Q · filed 2020-11-05 | 25.41M shares derived: average of 4 quarters · filed 2021-05-06 |
| 2020-06-30 | 37.59M shares 10-Q · filed 2020-08-11 | 30.92M shares 10-Q · filed 2020-08-11 | 21.30M shares derived: average of 3 quarters · filed 2021-05-06 | 16.45M shares derived: average of 4 quarters · filed 2021-05-06 |
| 2020-03-31 | 24.26M shares 10-Q · filed 2021-05-06 | 13.16M shares derived: average of 2 quarters · filed 2021-05-06 | 9.41M shares derived: average of 3 quarters · filed 2021-05-06 | 7.50M shares derived: average of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | 2.05M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | 1.98M shares derived: average of 2 quarters · filed 2021-02-16 | 1.91M shares derived: average of 3 quarters · filed 2021-02-16 | 1.84M shares 10-K · filed 2021-02-16 |
| 2019-09-30 | 1.92M shares 10-Q · filed 2020-11-05 | 1.84M shares derived: average of 2 quarters · filed 2020-11-05 | 1.77M shares 10-Q · filed 2020-11-05 | |
| 2019-06-30 | 1.77M shares 10-Q · filed 2020-08-11 | 1.70M shares 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | 1.63M shares 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | 1.24M shares 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |